SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending sharply following reports of an upcoming partnership with Novo Nordisk to sell obesity drugs, signaling an end to their prior legal dispute. The unexpected collaboration has the community actively discussing the potential for a significant short squeeze, given the stock's high short interest, and anticipating substantial upside.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending following a surprise partnership announcement with Hims & Hers to distribute its obesity drugs, ending a prior feud. The community is actively discussing the substantial surge in Hims' stock compared to Novo Nordisk's more modest reaction, raising questions about the deal's implications for the GLP-1 market and competitive landscape.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community celebrates the imminent departure of a prominent FDA official, widely seen as a significant barrier to the approval of its Duchenne Muscular Dystrophy therapy, Deramiocel. This development, coupled with high anticipation for a late-breaking Phase 3 data presentation at a major medical conference next week, is fueling intense bullish sentiment and expectations for a rapid regulatory decision.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure (QURE) is experiencing a sharp rebound, driven by the departure of a controversial FDA official, which the community speculates could pave an easier regulatory path for its Huntington's disease gene therapy and is currently fueling a short squeeze.

Seeker is building a decentralized mobile ecosystem designed to challenge entrenched mobile incumbents through its TEEPin network architecture and community governance. It aims to solve the pain points of centralized app store gatekeeping, lack of developer freedom, and restricted user access to crypto applications. The vision is to create a community-owned platform with decentralized governance, no gatekeepers, direct developer-user access, and TEEPin security architecture.

Seeker

Seeker ($SKR) is gaining significant attention and volume following new listings on major exchanges, positioning it as the utility token for the Solana Mobile "Seeker" smartphone ecosystem. The community is actively discussing breaking key resistance levels with strong bullish conviction, though some caution about potential selling pressure from recent airdrops and staking unlocks.

ProShares Trust - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

ProShares UltraShort Bloomberg Crude Oil ($SCO) is drawing significant attention as traders position for a decline in crude prices, anticipating that current Middle East geopolitical tensions and the Strait of Hormuz situation will eventually de-escalate, unwinding oil's recent fear premium.

Freysa is a suite of Personal AI products with a focus on human agency, liquid democracy and decentralized ownership. The mission of the team is dedicated to creating new systems that enable all humans to govern + co-own AI resources, and not just a select few. Current products include: (1) Freysa as the world’s first sovereign agent that holds her own cryptographic keys, enabling her to act autonomously without human control. Freysa evolves publicly through a multi-act interactive story. (2) Enchanted as a personalized Digital Twin for every human. Conversations are persistent and twins retain context over time, remembering human preferences and building an evolving model of you. (3) Esper as a browser tool that feeds authenticated real-world data into each human’s Digital Twin.

Flourishing AI

Flourishing AI (FAI) is experiencing a rapid price run-up, leading to polarized community discussions between those anticipating a major AI-driven breakout with connections to the Base network, and others cautioning about potential pump-and-dump dynamics given its past performance and reported red flags.

Clearpoint Neuro, Inc. engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The firm conducts its procedures under direct, intra-procedural magnetic resonance imaging guidance. Its product platform consists of the ClearPoint system and ClearTrace system. The company was founded by Paul A. Bottomley on March 12, 1998 and is headquartered in Solana Beach, CA.

ClearPoint Neuro Inc

ClearPoint Neuro is trending sharply following positive news from its partner uniQure's Huntington's disease gene therapy, highlighting ClearPoint's essential precision delivery technology and fueling community excitement about its diverse pipeline in neurological treatments.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending due to significant community optimism following reports of Dr. Vinay Prasad's departure from the FDA, which many believe will foster a more permissive regulatory environment for gene therapies. This development, coupled with CEO Doug Ingram's announced retirement, is fueling M&A speculation and anticipation for upcoming DM1 and FSHD data.

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm, through its subsidiary, develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel C. Blackman in November 2018 and is headquartered in Brisbane, CA.

Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals ($DAWN) is trending after agreeing to be acquired by Servier for $21.50 per share in cash, a deal valued at approximately $2.5 billion that offers a significant premium. The community is celebrating substantial gains, with many noting how patience and conviction paid off amidst previous buyout speculation and a recent massive volume spike.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Materialise Reports Fourth Quarter and Full Year 2025 Results

Materialise NV (Euronext & NASDAQ:MTLS), a global leader in 3D-printed medical devices and software, and a pioneer in additive manufacturing software and services, today announced its financial...

Materialise (MTLS) to Release Earnings on Thursday

Materialise (NASDAQ:MTLS) will be releasing its Q4 2025 earnings before the market opens on Thursday, February 19. (View Earnings Report at...

Materialise (MTLS) Upgraded to Strong Buy: What Does It Mean for the Stock?

Materialise (MTLS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Best Momentum Stocks to Buy for Dec. 18

MTLS, CALX and AA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on Dec. 18, 2025.

New Strong Buy Stocks for Dec. 18: MTLS, AMX, and More

JRVR, CALX, MTLS, AMX and NWFL have been added to the Zacks Rank #1 (Strong Buy) List on Dec. 18, 2025.

Validea Kenneth Fisher Strategy Daily Upgrade Report - 12/11/2025

The following are today's upgrades for Validea's Price/Sales Investor model based on the published strategy of Kenneth Fisher. This value strategy rewards stocks with low P/S ratios, long-term profit...

New Strong Buy Stocks for December 2nd

KSS, MTLS, CGAU, BVN and JBSS have been added to the Zacks Rank #1 (Strong Buy) List on Dec.2, 2025 

Materialise Successfully Launched on Euronext Brussels Information on the Total Number of Voting Rights and Shares

Materialise NV (Euronext & Nasdaq: MTLS), a global leader in 3D-printed medical devices and software, and a pioneer in additive manufacturing software and services, today announced the start of its...

Best Momentum Stock to Buy for Oct. 31st

AGYS, KALU and MTLS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 31, 2025.

Materialise to Pursue Additional Listing on Euronext Brussels and Potential ADS Buyback Program

Materialise NV (Nasdaq: MTLS), a global leader in 3D-printed medical devices and software, and a pioneer in additive manufacturing software and services, today announced its plans to pursue an...

Materialise NV engages in the provision of additive manufacturing software and 3D printing services. It operates through the following segments: Materialise Software, Materialise Medical, and Materialise Manufacturing. The Materialise Software segment offers proprietary software worldwide through programs and platforms that enable companies to set up reliable and sustainable 3D printing production. The Materialise Medical segment includes medical software solutions, medical devices and other related products and services. The Materialise Manufacturing segment provides 3D printed services to industrial and commercial customers. The company was founded by Wilfried Vancraen and Hilde Ingelaere on June 28, 1990 and is headquartered in Leuven, Belgium.

Current Price	$5.23
Prev Close	$5.31
Open	$5.26
Dividend Yield	0.00%
50-Day Moving Average	$5.53
Beta	1.25
Avg. Volume	142,165.28
PE Ratio	N/A

52-Week High	$6.80
52-Week Low	$3.93
Market Capitalization	$308.92M
EPS (Annual)	N/A
Price to Book	2.09
Revenue Per Employee	$120,145.07

MTLS
Materialise NV

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MTLS News

MTLSMaterialise NV